The ADNA program partners will synergistically focus on three main research themes for development of new products:
the discovery and validation of biomarkers:
This activity involves bioMérieux, Hospices Civils de Lyon, GenoSafe, Généthon and Transgene, using shared technological approaches such as the analysis of gene expression, proteomic analyses, immunological and cellular tracking.
In terms of therapy, the partners "various clinical trials will allow access to patients" samples in order to conduct research on biomarkers. The areas of biomarker research are the following:
bioMérieux is also developing, in partnership with pharmaceutical partners (IPSEN and others),
approaches to companion tests with biomarkers associated with their therapeutic molecule.
The discovery and validation of biomarkers also entails the development and common provision of tools and expertise in bioinformatics, biomathematics, biostatistics and knowledge engineering to ultimately create software for interpreting results.
Généthon and Transgene study viral vectors such as AAV (Adeno Associated Viruses) and MVA (Modified attenuated Vaccinia virus, strain Ankara) to develop their respective therapies. Beyond the construction of these recombinant vectors that contain therapeutically-important genes, the targeted objectives for administration in humans requires the development of special manufacturing processes based on culturing cells.
The quantities to produce for treating a large population of patients, combined with the regulatory requirements for efficacy and safety of human injectable products, require the development of unique industrial processes for each product that are still relatively uncommon in the pharmaceutical industry.
The efforts of the consortium bear on the development of cells capable of producing recombinant viruses and infrastructures for production of clinical lots and volumes of products for distribution.
microsystems for diagnostics:
The development of diagnostic systems for the analysis or dosage of biomarkers requires integration of a large number of additional technologies. The analysis of a combination of biomarkers (for example the expression of several genes) from a single laboratory sample is a tedious, time-consuming and costly process for specialized research and highly-qualified laboratories. One of the challenges is to simplify the analysis protocols and automate,with innovative technologies, the diagnostic tests procedures (parallelized PCR, sequencing...) conducted by a larger number of laboratories.
To do this, bioMérieux, CEA, STMicroelectronics, CNRS and UCBL are
working to develop microsystems (laboratories on microchips) to simplify and make the analyses reliable
and reproducible for use on routine clinical samples. The technologies and research work on DNA microchips,
called "Lab-on-a-chip", sensors and signal analysis systems, and all necessary elements for development
of instruments and associated reagents for molecular diagnosis.
The goal of ADNA is to promote development of innovative products and services in the following complementary areas:
In vitro diagnosis by bioMérieux, in association with its partners CEA, CNRS, HCL, STMicroelectronics and UCBL :
Services for research and development of new biotherapy products by GenoSafe:
Rare genetic diseases, by Généthon:
Therapeutic vaccines against infectious diseases and cancer, by Transgene: